Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40.
Jaff MR, Rosenfield K, Scheinert D, Rocha-Singh K, Benenati J, Nehler M, et al. Drug-coated balloons to improve femoropopliteal artery patency: rationale and design of the LEVANT 2 trial. Am Heart J. 2015;169:479–85.
Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–8.
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.
Schroeder H, Werner M, Meyer DR, Reimer P, Krüger K, Jaff MR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty Balloon). Circulation. 2017;135:2227–36.
Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.
Gardiner GA Jr, Bonn J, Sullivan KL. Quantification of elastic recoil after balloon angioplasty in the iliac arteries. J Vasc Interv Radiol. 2001;12:1389–93.
Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23:356–70.
Mathlouthi A, Yei KS, Naazie I, Bertges DJ, Malas MB. Increased mortality with paclitaxel-eluting stents is driven by lesion length. J Vasc Surg. 2020.
Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e0011245.
Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–63.
Radke PW, Joner M, Joost A, Byrne RA, Hartwig S, Bayer G, et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention. 2011;7:730–7.
Banerjee S, Khalili H. Drug-coated balloon for long femoropopliteal lesions. Circ Cardiovasc Interv. 2018;11:e007084.
Micari A, Vadalà G, Castriota F, Liso A, Grattoni C, Russo P, et al. 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study. JACC Cardiovasc Interv. 2016;9:950–6.
Micari A, Nerla R, Vadalà G, Castriota F, Grattoni C, Liso A, et al. 2-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study. JACC Cardiovasc Interv. 2017;10:728–34.
Scheinert D, Micari A, Brodmann M, Tepe G, Peeters P, Jaff MR, et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv. 2018;11:e005654.
Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P, et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther. 2020:1526602820931477.
Li X, Zhou M, Ding Y, Wang Y, Cai L, Shi Z. A systematic review and meta-analysis of the efficacy of debulking devices for in-stent restenosis of the femoropopliteal artery. J Vasc Surg. 2020;72:356-366.e5.
Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol. 2011;46:255–63.
Okuno S, Iida O, Shiraki T, Fujita M, Masuda M, Okamoto S, et al. Impact of calcification on clinical outcomes after endovascular therapy for superficial femoral artery disease: assessment using the peripheral artery calcification scoring system. J Endovasc Ther. 2016;23:731–7.
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–79.
Mohapatra A, Saadeddin Z, Bertges DJ, Madigan MC, Al-Khoury GE, Makaroun MS, et al. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. J Vasc Surg. 2020;71:560–6.
Newman AB, Naydeck BL, Whittle J, Sutton-Tyrrell K, Edmundowicz D, Kuller LH. Racial differences in coronary artery calcification in older adults. Arterioscler Thromb Vasc Biol. 2002;22:424–30.
Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I Trial. JACC Cardiovasc Interv. 2016;9:1941–9.
Xu Y, Jia X, Zhang J, Zhuang B, Fu W, Wu D, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I. JACC Cardiovasc Interv. 2018;11:2347–53.
Chou HH, Huang HL, Hsieh CA, Jang SJ, Tzeng IS, Ko YL. Drug-Coated Balloon versus conventional balloon angioplasty in dialysis patients with symptomatic femoropopliteal disease—a matched comparison. Circ J. 2018;82:1908–16.
AbuRahma AF, AbuRahma ZT, Scott G, Adams E, Beasley M, Davis M, et al. Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: a real-world single-center experience. J Vasc Surg. 2019;70:1950–9.
Schmidt A, Piorkowski M, Görner H, Steiner S, Bausback Y, Scheinert S, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–24.
Hsieh CA, Chou SH, Chen IC, Jang SJ, Chou HH, Ko YL, et al. Feasibility and mid-term outcomes of drug-coated balloon angioplasty between intermittent claudication and critical limb ischemia in patients with femoropopliteal disease. Acta Cardiol Sin. 2019;35:308–19.
Gray WA, Jaff MR, Parikh SA, Ansel GM, Brodmann M, Krishnan P, et al. Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the illumenate clinical program at 3 years. Circulation. 2019;140:1145–55.
Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Peña C, et al. Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv. 2019;12:2515–24.